{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:34:21Z","timestamp":1791416061344,"version":"4.3.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,7,19]],"date-time":"2014-07-19T00:00:00Z","timestamp":1405728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s00259-014-2839-y","type":"journal-article","created":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T12:04:23Z","timestamp":1405685063000},"page":"2008-2016","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma"],"prefix":"10.1007","volume":"41","author":[{"given":"Charles","family":"Lemarignier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Di Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charline","family":"Marre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Hapdey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Modzelewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierrick","family":"Gouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Dubray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,19]]},"reference":[{"key":"2839_CR1","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400\u201312.","journal-title":"Lancet"},{"key":"2839_CR2","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.3748\/wjg.v19.i34.5598","volume":"19","author":"Y Zhang","year":"2013","unstructured":"Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19:5598\u2013606.","journal-title":"World J Gastroenterol"},{"key":"2839_CR3","unstructured":"Institut National du Cancer. La situation du cancer en France en 2010. Collection Rapports & synth\u00e8ses. Boulogne-Billancourt: INCa; novembre 2010."},{"key":"2839_CR4","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMra035010","volume":"349","author":"PC Enzinger","year":"2003","unstructured":"Enzinger PC, Mayer RJ. Esophageal cancer. New Engl J Med. 2003;349:2241\u201352.","journal-title":"New Engl J Med"},{"key":"2839_CR5","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1200\/JCO.2007.12.4289","volume":"25","author":"L Bedenne","year":"2007","unstructured":"Bedenne L, Michel P, Bouch\u00e9 O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:4025\u20136.","journal-title":"J Clin Oncol"},{"key":"2839_CR6","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2004.01.083","volume":"22","author":"HL Westreenen Van","year":"2004","unstructured":"Van Westreenen HL, Westerterp M, Bossuyt PMM, Pruim J, Sloof GW, van Lanschot JJB, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 2004;22:3805\u201312.","journal-title":"J Clin Oncol"},{"key":"2839_CR7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.bjc.6604200","volume":"98","author":"EP Vliet Van","year":"2008","unstructured":"Van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98:547\u201357.","journal-title":"Br J Cancer"},{"key":"2839_CR8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1200\/JCO.2003.04.013","volume":"21","author":"RJ Downey","year":"2003","unstructured":"Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21:428\u201332.","journal-title":"J Clin Oncol"},{"key":"2839_CR9","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1245\/s10434-011-1732-1","volume":"18","author":"JM Omloo","year":"2011","unstructured":"Omloo JM, van Heijl M, Hoekstra OS, van Berge Henegouwen MI, van Lanschot JJ, Sloof GW. FDG-PET parameters as prognostic factor in esophageal cancer patients: a review. Ann Surg Oncol. 2011;18:3338\u201352.","journal-title":"Ann Surg Oncol"},{"key":"2839_CR10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00259-012-2280-z","volume":"40","author":"C Wiele Van de","year":"2013","unstructured":"Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40:290\u2013301.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2839_CR11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.dld.2012.04.017","volume":"44","author":"F Fiore Di","year":"2012","unstructured":"Di Fiore F, Blondin V, Hitzel A, Edet-sanson A, Benyoucef A, Huet E, et al. 18F-fluorodeoxyglucose positron emission tomography after definitive chemoradiotherapy in patients with oesophageal carcinoma. Dig Liver Dis. 2012;44:875\u20139.","journal-title":"Dig Liver Dis"},{"key":"2839_CR12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.canrad.2008.07.001","volume":"12","author":"E Touboul","year":"2008","unstructured":"Touboul E, Huguet F, Talbot J-N. Use of PET for staging, treatment evaluation, and follow-up in esophageal cancers. Cancer Radiother. 2008;12:633\u20139.","journal-title":"Cancer Radiother"},{"key":"2839_CR13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1148\/radiol.09091324","volume":"254","author":"RM Kwee","year":"2010","unstructured":"Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology. 2010;254:707\u201317.","journal-title":"Radiology"},{"key":"2839_CR14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00259-013-2450-7","volume":"40","author":"O Palie","year":"2013","unstructured":"Palie O, Michel P, M\u00e9nard J-F, Rousseau C, Rio E, Bridji B, et al. The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3). Eur J Nucl Med Mol Imaging. 2013;40:1345\u201355.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2839_CR15","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1200\/JCO.2004.07.122","volume":"22","author":"HA Wieder","year":"2004","unstructured":"Wieder HA, Br\u00fccher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900\u20138.","journal-title":"J Clin Oncol"},{"key":"2839_CR16","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s00259-013-2468-x","volume":"40","author":"RL Blom","year":"2013","unstructured":"Blom RL, Steenbakkers IR, Lammering G, Vliegen RF, Belgers EJ, de Jonge C, et al. PET\/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:1500\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2839_CR17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1245\/s10434-009-0719-7","volume":"17","author":"SH Hyun","year":"2010","unstructured":"Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17:115\u201322.","journal-title":"Ann Surg Oncol"},{"key":"2839_CR18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/COC.0b013e31803993f8","volume":"30","author":"M Mamede","year":"2007","unstructured":"Mamede M, Abreu-E-Lima P, Oliva MR, Nos\u00e9 V, Mamon H, Gerbaudo VH. FDG-PET\/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol. 2007;30:377\u201388.","journal-title":"Am J Clin Oncol"},{"key":"2839_CR19","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00259-011-1834-9","volume":"38","author":"M Hatt","year":"2011","unstructured":"Hatt M, Visvikis D, Pradier O, Cheze-le RC. Baseline 18F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer. Eur J Nucl Med Mol Imaging. 2011;38:1595\u2013606.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2839_CR20","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1259\/bjr\/79854022","volume":"85","author":"W-Q Zhu","year":"2012","unstructured":"Zhu W-Q, Sun X, Xing L, Li M, Yue J, Qu W, et al. Oesophageal squamous cell carcinoma: relationship between fluorine-18 fludeoxyglucose positron emission tomography CT maximum standardised uptake value, metabolic tumour volume, and tumour, node and metastasis classification. Br J Radiol. 2012;85:e383\u20137.","journal-title":"Br J Radiol"},{"key":"2839_CR21","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/annonc\/mdr433","volume":"23","author":"A Herskovic","year":"2012","unstructured":"Herskovic A, Russell W, Liptay M, Fidler MJ, Al-Sarraf M. Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol. 2012;23:1095\u2013103.","journal-title":"Ann Oncol"},{"key":"2839_CR22","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1088\/0031-9155\/54\/22\/010","volume":"54","author":"S Vauclin","year":"2009","unstructured":"Vauclin S, Doyeux K, Hapdey S, Vera P. Development of a generic thresholding algorithm for the delineation of 18FDG-PET-positive tissue: application to the comparison of three thresholding. Phys Med Biol. 2009;54:6901\u201316.","journal-title":"Phys Med Biol"},{"key":"2839_CR23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11307-008-0169-9","volume":"11","author":"JB Roedl","year":"2009","unstructured":"Roedl JB, Halpern EF, Colen RR, Sahani DV, Fischman AJ, Blake MA. Metabolic tumor width parameters as determined on PET\/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol. 2009;11:54\u201360.","journal-title":"Mol Imaging Biol"},{"key":"2839_CR24","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1097\/MNM.0b013e3283573d0d","volume":"33","author":"P Fencl","year":"2012","unstructured":"Fencl P, Belohlavek O, Harustiak T, Zemanova M. The analysis of factors affecting the threshold on repeated 18F-FDG-PET\/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma. Nucl Med Commun. 2012;33:1188\u201394.","journal-title":"Nucl Med Commun"},{"key":"2839_CR25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/01.coc.0000242346.25229.48","volume":"29","author":"G Cr\u00e9hange","year":"2006","unstructured":"Cr\u00e9hange G, Bosset M, Lorchel F, Fabrice L, Buffet-Miny J, Dumas JL, et al. Tumor volume as outcome determinant in patients treated with chemoradiation for locally advanced esophageal cancer. Am J Clin Oncol. 2006;29:583\u20137.","journal-title":"Am J Clin Oncol"},{"key":"2839_CR26","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00259-011-1755-7","volume":"38","author":"M Hatt","year":"2011","unstructured":"Hatt M, Visvikis D. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011;38:1191\u2013202.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2839_CR27","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/01.sla.0000208430.07050.61","volume":"243","author":"EA Levine","year":"2006","unstructured":"Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, et al. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472\u20138.","journal-title":"Ann Surg"},{"key":"2839_CR28","first-page":"1710","volume":"133","author":"J Gerdes","year":"1984","unstructured":"Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. Eur J Cancer. 1984;133:1710\u20135.","journal-title":"Eur J Cancer"},{"key":"2839_CR29","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s00259-007-0449-7","volume":"34","author":"Y Yamamoto","year":"2007","unstructured":"Yamamoto Y, Nishiyama Y. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:1610\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2839_CR30","first-page":"3837","volume":"6","author":"H Vesselle","year":"2000","unstructured":"Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837\u201344.","journal-title":"Clin Cancer Res"},{"key":"2839_CR31","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/j.ejrad.2009.11.020","volume":"75","author":"S Murakami","year":"2010","unstructured":"Murakami S, Saito H, Sakuma Y, Mizutani Y, Ishikawa Y, Ito H, et al. Correlation of 18F-fluorodeoxyglucose uptake on positron emission tomography with Ki-67 index and pathological invasive area in lung adenocarcinomas 30\u00a0mm or less in size. Eur J Radiol. 2010;75:e62\u20136.","journal-title":"Eur J Radiol"},{"key":"2839_CR32","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/MNM.0b013e32832dcfc4","volume":"30","author":"B Han","year":"2009","unstructured":"Han B, Lin S, Yu L, Wang R, Wang Y. Correlation of 18F-FDG PET activity with expressions of survivin, Ki67, and CD34 in non-small-cell lung cancer. Nucl Med Commun. 2009;30:831\u20137.","journal-title":"Nucl Med Commun"},{"key":"2839_CR33","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.surg.2014.01.009","volume":"155","author":"A Sueta","year":"2011","unstructured":"Sueta A, Yamamoto Y, Hayashi M, Yamamoto S. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer; is it equally useful across tumor subtypes? Surgery. 2011;155:927\u201335.","journal-title":"Surgery"},{"key":"2839_CR34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0959-8049(03)00675-0","volume":"40","author":"T Petit","year":"2004","unstructured":"Petit T, Wilt M, Velten M, Millon R, Rodier J, Borel C. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004;40:205\u201311.","journal-title":"Eur J Cancer"},{"key":"2839_CR35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1023\/A:1022165715043","volume":"78","author":"G Pohl","year":"2003","unstructured":"Pohl G, Rudas M, Taucher S, Stranzl T, Steger GG, Jakesz R, et al. Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat. 2003;78:97\u2013103.","journal-title":"Breast Cancer Res Treat"},{"key":"2839_CR36","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1245\/s10434-013-3335-5","volume":"21","author":"P-C Yam","year":"2013","unstructured":"Yam P-C, Tong D, Law S. Comparisons of sixth and seventh edition of the American Joint Cancer Committee staging systems for esophageal cancer. Ann Surg Oncol. 2013;21:583\u20138.","journal-title":"Ann Surg Oncol"},{"key":"2839_CR37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00508-012-0310-2","volume":"125","author":"N Wu","year":"2013","unstructured":"Wu N, Chen Z, Pang L, Ma Q, Chen G. Prognostic significance of lymph node characteristics on survival in esophageal squamous cell carcinomas. Wien Klin Wochenschr. 2013;125:26\u201333.","journal-title":"Wien Klin Wochenschr"},{"key":"2839_CR38","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1245\/s10434-012-2656-0","volume":"20","author":"D Situ","year":"2013","unstructured":"Situ D, Wei W, Lin P, Long H, Zhang L, Fu J, et al. Do tumor grade and location affect survival in esophageal squamous cell carcinoma? Survival analysis of 302 cases of pT3N0M0 esophageal squamous cell carcinoma. Ann Surg Oncol. 2013;20:580\u20135.","journal-title":"Ann Surg Oncol"},{"key":"2839_CR39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1471-2407-11-164","volume":"11","author":"M Bashash","year":"2011","unstructured":"Bashash M, Hislop TG, Shah AM, Le N, Brooks-Wilson A, Bajdik CD. The prognostic effect of ethnicity for gastric and esophageal cancer: the population-based experience in British Columbia, Canada. BMC Cancer. 2011;11:164.","journal-title":"BMC Cancer"},{"key":"2839_CR40","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/cncr.10868","volume":"95","author":"MA Eloubeidi","year":"2002","unstructured":"Eloubeidi MA, Desmond R, Arguedas MR, Reed CE. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S. The importance of tumor length and lymph node status. Cancer. 2002;95:1434\u201343.","journal-title":"Cancer"},{"key":"2839_CR41","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00259-013-2465-0","volume":"40","author":"NE Makris","year":"2013","unstructured":"Makris NE, Huisman MC, Boellaard R. Evaluation of strategies towards harmonization of FDG PET\/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures. Eur J Nucl Med Mol Imaging. 2013;40:1507\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-014-2839-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-014-2839-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-014-2839-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:06:20Z","timestamp":1558699580000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-014-2839-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,19]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["2839"],"URL":"https:\/\/doi.org\/10.1007\/s00259-014-2839-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,19]]}}}